Neb­u­liz­er fails PhII COPD study, but Verona plans to march on

Billed as the first new class of bron­chodila­tor in more than four decades, Verona Phar­ma’s $VR­NA ex­per­i­men­tal neb­u­liz­er did not con­fer sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER